In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
In an expanded phase 2 trial evaluating the addition of tislelizumab to a HMA plus CAG chemotherapy regimen for patients with high-risk R/R acute myeloid leukemia, what was the reported overall response rate in the group treated with...
Rami Komrokji, MD; Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO
This discussion between experts addresses unmet needs in the acute myeloid leukemia treatment landscape (AML) and the efficacy and safety of a treatment option for patients with relapsed and refractory AML with isocitrate dehydrogenase 1...
This discussion between experts addresses unmet needs in the acute myeloid leukemia treatment landscape (AML) and the efficacy and safety of a treatment option for patients with relapsed and refractory AML with isocitrate dehydrogenase 1...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
